Since l-asparaginase, a component of the VXL standard-of-care chemotherapy, contains GLS-inhibiting activity, we next focused on metabolic consequences induced by VXL-chemotherapy in T-ALL. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.